Furthermore, augmented IL-1β and NLRP3-inflammasome activation was described as a major driver of atherosclerosis in mice with hematopoietic Tet2 deficiency, and pharmacologic inhibition of the inflammasome significantly reduced the proatherogenic effect of Tet2-deficient myeloid cells [30]. The gene discussed is TET2; the disease is atherosclerosis.